Michael John Appointed VP of Cardiovascular Regulatory Affairs of MCRA

VERITAS Vision System Is Introduced by Johnson & Johnson

The company will offer live demos of the new system in a wet lab at the Johnson & Johnson booth (#2813) this weekend at the 2021 American Society of Cataract and Refractive Surgery and American Society of Ophthalmic Administrators Annual Meeting.

GenesisCare Orders 27 Elekta Flexitron Treatment Devices

"GenesisCare continues to demonstrate its commitment to improving patient outcomes worldwide and Elekta is delighted to play a vital partnering role to achieve this mission," said Gustaf Salford, Elekta's President and CEO.

FoodMarble AIRE Shown to Exceed the Performance of ‘Gold Standard’ SIBO Testing in Clinical Trial

SIBO is a very common disorder where there are excessive bacteria present in the small intestine. The true prevalence of SIBO in the general population is largely unknown, with some studies estimating its occurrence in up to 15% of healthy individuals. It is also largely associated with many other common clinical conditions, including irritable bowel syndrome, where 40-80% of IBS patients have SIBO.

Michael C. John, MPH, has been appointed new Vice President of Cardiovascular Regulatory Affairs.

Michael C. John, MPH joined MCRA from the US Food and Drug Administration, where he was Chief of the Interventional Cardiology Devices Branch. In his position, Michael supervised and provided leadership for a multi-disciplinary team of scientists and health care professionals on the regulation of interventional cardiovascular Class II and Class III medical devices. As Branch Chief, Michael reviewed and edited scientific memoranda from staff relating to all regulatory decisions on PMA, IDE, and 510(k) medical device submissions pertaining to coronary interventional products. He also functioned as a focal point for industry representatives, Advisory Panel members, scientific experts and cardiovascular thought leaders in discussing the regulation of products in the rapidly evolving interventional cardiovascular device arena.

Michael has extensive knowledge of medical device regulations and regulatory pathways to drive a device from conception to market. Prior to becoming Branch Chief, Michael was an Animal Testing Reviewer and Lead Reviewer in the Division of Cardiovascular Devices at FDA. Before joining FDA, Michael conducted cardiovascular research at The Massachusetts General Hospital in Boston, MA where he specialized in cardiovascular pathology and histology, and performed countless stent implantation procedures in animal models.

David Lown, MCRA’s General Manager said, “Beginning in 2004 MCRA has led the medical device model of deep industry specialization and service integration to assist industry in bringing innovation to patients. Michael is a recognized expert with an extensive background in cardiovascular device regulation and physiology, and his appointment reflects MCRA’s strong commitment to providing first-rate regulatory services to the cardiovascular community. We are honored Michael has joined MCRA. He will make a tremendous impact.”

Michael John said, “It is a privilege to join the distinguished team at MCRA at such an exciting time in the history of cardiovascular innovation,” said Michael John.  “MCRA has a long track record of success in the device arena and has established a strong foundation for growth into the cardiovascular field.  I look forward to leading the MCRA Cardio team to bring the next wave of innovative cardiovascular products and solutions to patients in need.”



Our Sister Publication: Biotechnology News Magazine

Subscribe to Medical Device News Magazine here.